Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a
Rania M. El-Lababidi,
Mohamad Mooty,
Maria-Fernanda Bonilla,
Nouran M. Salem
Affiliations
Rania M. El-Lababidi
Department of Pharmacy Services, Cleveland Clinic Abu Dhabi, Al Maryah Island, p.o. box 112412, Abu Dhabi, United Arab Emirates; Corresponding author.
Mohamad Mooty
Department of Infectious Diseases, Medical Subspecialties Institute, Cleveland Clinic Abu Dhabi, Al Maryah Island, Abu Dhabi, p.o. box 112412, United Arab Emirates
Maria-Fernanda Bonilla
Department of Infectious Diseases, Medical Subspecialties Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
Nouran M. Salem
Department of Pharmacy Services, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
The outbreak of the new coronavirus disease 2019 (COVID-19) has spread rapidly worldwide. Until now, no definite effective treatment has been identified. We reported 3 patients with severe COVID-19 treated with pegylated interferon alfa 2a with satisfactory recovery. Based on these observations, randomized studies with interferons should be considered in deteriorating patients infected with COVID-19.
